EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management

Animesh Pardanani

American Journal of Hematology · 2026-09 · 101 (9) · 2371-2392

DOI: 10.1002/ajh.70395 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 17.06.2026. Verfasst von Animesh Pardanani. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mastocytosis, Systemic. Die Arbeit nennt 153 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extra‐cutaneous organs. Diagnosis The major criterion is the presence of multifocal MC clusters in the bone marrow and/or extracutaneous organs. Minor diagnostic criteria include elevated serum tryptase level, MC CD25/CD2/CD30 expression, and the presence of activating KIT mutations. Risk Stratification Establishing SM subtype as per the International Consensus Classification/World Health Organization classification systems is an important first step. Patients either have indolent/smoldering SM (ISM/SSM) or advanced SM, including aggressive SM (ASM), SM with associated myeloid neoplasm (SM‐AMN), or mast cell leukemia. Identification of poor‐risk mutations (i.e., ASXL1, RUNX1, SRSF2, NRAS ) further refines the risk stratification. Several risk models are available to help assign prognosis in SM patients. Management Treatment goals for ISM patients are primarily directed towards anaphylaxis prevention/symptom control/osteoporosis treatment. Patients with advanced SM frequently need MC cytoreductive therapy to reverse disease‐related organ dysfunction. Tyrosine kinase inhibitors (TKI) (midostaurin, avapritinib) have changed the treatment landscape in SM. While deep biochemical, histological, and molecular responses have been documented with avapritinib treatment, its efficacy as monotherapy against a multimutated AMN disease component in SM‐AMN patients remains unclear. Cladribine continues to have a role for MC debulking, whereas interferon‐α has a diminishing role in the TKI era. Treatment of SM‐AMN primarily targets the AMN component, particularly if an aggressive disease such as acute leukemia is present. Allogeneic stem cell transplant has a role in such patients. Imatinib has a therapeutic role only in the rare patient with an imatinib‐sensitive KIT mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, SystemicHumansAdultProtein Kinase InhibitorsRisk AssessmentMutationProto-Oncogene Proteins c-kitMast CellsPrognosisDisease ManagementAvapritinibTryptasesStaurosporine

Substanzen

midostaurinProtein Kinase InhibitorsProto-Oncogene Proteins c-kitKIT protein, humanAvapritinibTryptasesStaurosporine

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Zitieren

APA

Pardanani, A. (2026). Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management. American Journal of Hematology, 101(9), 2371-2392. https://doi.org/10.1002/ajh.70395

Vancouver

Pardanani A. Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management. American Journal of Hematology. 2026;101(9):2371-2392. doi:10.1002/ajh.70395

BibTeX
@article{Pardanani2026,
  author = {Pardanani, Animesh},
  title = {Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {9},
  pages = {2371--2392},
  doi = {10.1002/ajh.70395}
}
Kostenlos starten →